Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
Heart Failure
Empagliflozin: Cardio-Renal Benefits in HF, LVEF Above 40% Regardless of CKD Status
The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes.
CaroSpir, a Liquid Form of Spironolactone, Now Available in Unit Dose Cups
The new packaging allows for ease of administration and convenience.
SGLT2 Inhibitors May Cut Risk for Heart Failure Hospitalization
SGLT2 inhibitors, compared with GLP-1 RAs, linked to lower risk for heart failure hospitalization in patients with T2DM, with or without CVD
Left Ventricular Assist Devices Aid Survival, Quality of Life in Elderly
Benefits for heart failure patients include functional capacity and fewer complications with newer devices
Empagliflozin Gets Breakthrough Tx Status for Heart Failure With Preserved Ejection Fraction
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Higher Maternal Lipid Profile Tied to Congenital Heart Disease in Offspring
Doubled risk seen for high triglyceride, total/high-density lipoprotein, and apolipoprotein-A1
MPR Weekly Dose Podcast Episode 90
This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another Jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.
